BiotechTube
Home/Pipeline/Fragile X Syndrome Candidate

Fragile X Syndrome Candidate

Fragile X Syndrome (FXS)

Phase 3Active

Key Facts

Indication
Fragile X Syndrome (FXS)
Phase
Phase 3
Status
Active
Company
Shionogi

About Shionogi

Shionogi is a premier, discovery-based Japanese pharmaceutical company with a 65+ year legacy in antibiotic innovation and a mission to supply the best possible medicine to protect patient health. The company has successfully diversified its pipeline beyond its core infectious disease expertise into antivirals, CNS disorders, and rare diseases, while maintaining a steadfast commitment to combating antimicrobial resistance (AMR). Its strategy combines deep in-house R&D capabilities with strategic global partnerships and licensing to accelerate development and commercialize novel therapeutics for serious unmet medical needs worldwide.

View full company profile

Therapeutic Areas

Infectious DiseasesCentral Nervous System (CNS)Rare DiseasesVirologyOncology

Other Fragile X Syndrome (FXS) Drugs

DrugCompanyPhase
CTH120Connecta TherapeuticsPhase 2 (Preparation)
FMR1 ProgramQuiver BioscienceDiscovery